Article

Angina in thyrotoxicosis. Thyroid-related coronary artery spasm

University of Washington Seattle, Seattle, Washington, United States
Archives of Internal Medicine (Impact Factor: 13.25). 04/1983; 143(3):554-5. DOI: 10.1001/archinte.1983.00350030168028
Source: PubMed

ABSTRACT Ischemic heart disease is a common complication of thyrotoxicosis, although the exact mechanism has not been defined. A case is reported of angina and thyrotoxicosis in which the angina was reproduced by coronary artery spasm induced by ergonovine maleate, relieved by thyroid ablation, and reactivated by postablative thyroid replacement. Coronary arteriography did not show significant stenoses prior to ergonovine injection. Possible mechanisms of coronary artery spasm in thyrotoxicosis are briefly discussed. Hyperthyroidism should be considered as a cause of angina in any patient with rest pain and normal coronary arteries.

0 Followers
 · 
162 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Zur Erhärtung der Bedeutung der latenten Hyperthyreose für das Auslösen von Vorhofflimmern wurden im Rahmen einer aus zwei Fall-Kontrollstudien kombinierten Analyse 295 Patienten mit Vorhofflimmern einer Kontrollgruppe mit 611 Patienten mit einem Sinusrhythmus gegenübergestellt. Der Schilddrüsenfunktionszustand beider Gruppen wurde beleuchtet. Bei 4,41 % der Patienten mit der Erstdiagnose eines Vorhofflimmerns und bei 1,84% der Patienten ohne Vorhofflimmern fand sich ein supprimiertes Serum-TSH bei normalen peripheren Schilddrüsenhormonen (Odds Ratio: 2,8). Patienten mit einer subklinischen Hyperthyreose (TSH-Werten <0,1 mU/l) hatten eine 2,8-fach höhere Wahrscheinlichkeit für Vorhofflimmern als Patienten mit einer normalen Schilddrüsenfunktion und sonst vergleichbarem Risikoprofil. Die Ergebnisse zeigen, dass eine subklinische Hyperthyreose ein von anderen Risikofaktoren unabhängiger und klinisch relevanter Risikofaktor für Vorhofflimmern darstellt.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The importance of cardiovascular system involvement in hyperthyroidism has been recognized for many years. In the middle-aged and elderly patient, often with mild but prolonged elevation of plasma thyroid hormones, symptoms and signs of heart failure and complicating atrial fibrillation may dominate the clinical picture and mask the more classical endocrine manifestations of the disease. Pitfalls in diagnosis and the importance of early recognition and treatment are discussed. Despite experimental evidence for a short-term inotropic action of thyroid hormone excess, clinical data support the existence of a reversible cardiomyopathy in hyperthyroidism with impaired contractile reserve. Enhanced myocardial performance at rest primarily reflects the peripheral actions of thyroid hormone excess. Most, if not all, of the cardiac abnormalities return to normal once a euthyroid state has been achieved, although atrial fibrillation may persist in a minority. Optimum treatment requires rapid and definitive antithyroid therapy, usually using a large dose of radio-iodine, and rapid control of heart failure. Systemic anticoagulation is indicated in the presence of atrial fibrillation and should be continued until sinus rhythm has been present for at least three months, either spontaneously or after cardioversion.
    Clinics in Endocrinology and Metabolism 06/1985; 14(2):491-508. DOI:10.1016/S0300-595X(85)80044-X
  • [Show abstract] [Hide abstract]
    ABSTRACT: We encountered 2 patients with thyrotoxicosis accompanied at its onset by progressive angina. The ST segment was elevated in one patient and depressed in the other patient during the spontaneous attacks. Coronary arteriographic findings were normal during control, and spasm was induced by ergonovine. No patients had chest pain even without antianginal medication after successful treatment of thyrotoxicosis. The coronary artery may become sensitive to spasm during thyroid hormone excess even in cases without significant coronary artery disease and previous chest pain.
    Angiology 10/1987; 38(9):717-22. DOI:10.1177/000331978703800910 · 2.37 Impact Factor